Alnylam Wins BIO s Helix Award; Some Past Winners Have Little to Show for It

Feb 16, 2006

Premium

The Biotechnology Industry Organization this week awarded Alnylam Pharmaceuticals the James D. Watson Helix award for corporate excellence in the emerging/mid-cap category.

The award, presented during BIO's annual CEO and Investor meeting in New York, honors leadership in scientific innovation, company growth, and corporate citizenship. It is presented by the Long Island Life Sciences Initiative, and is jointly sponsored by BIO, Stony Brook University, and The Center for Biotechnology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

To See More Clearly

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

Which Fish Is Which?

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

The Suspects, Too

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

This Week in PNAS

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.

Featured White Papers

Controlling Ribonuclease (RNase) with High Irradiance UV LED Light Engines

The Ultimate Guide to Mouse Clinical Trials

High Throughput RT-qPCR for Gene Expression Analysis

Mar

21

Featured Webinar

A Long-Read vs. Short-Read Platform Comparison (Part 2): Best NGS Approaches for Human Transcriptome Sequencing

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Apr

17

Featured Webinar

Biomarker Strategies for Optimizing Checkpoint Immunotherapy Treatment

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.

Menu